If you've taken kratom, you've taken speciogynine. You probably never knew it. The label on your bag almost certainly didn't mention it. And yet there it was, sitting inside every leaf at roughly 7% of total alkaloid content, doing whatever it does, while the bag's marketing copy talked about mitragynine and called it a day.
We get why people don't ask. The kratom shelf already has too many words on it (vein colors, strain names, percentages, certifications), and "speciogynine" sounds like the kind of thing only a chemistry forum cares about. But if you've ever wondered why two kratom products with the same mitragynine percentage feel different, the answer almost always involves the rest of the alkaloid panel, and speciogynine is part of that panel.
This guide is a careful walk through what speciogynine actually is, what researchers actually know about it as of 2026, and what it means for anyone who reads kratom labels closely. We're not selling speciogynine. There's nothing to sell. We're putting it in context next to the alkaloids you've heard of, with peer-reviewed sources cited inline, so the next time you read a strain breakdown you know what's actually being measured. In peer-reviewed work characterizing commercial kratom extracts, mitragynine made up around 66% of total alkaloid content, paynantheine roughly 9%, and speciogynine about 7%, with 7-hydroxymitragynine and speciociliatine making up the trace remainder (Kratom Alkaloids: Interactions With Enzymes, Receptors, and Cellular Barriers, PMC8637859). When we say speciogynine is "minor," that 7% is what we mean.
Table of Contents
- What Speciogynine Actually Is
- What Researchers Know About Speciogynine's Effects
- Where Speciogynine Sits in Real Kratom Products
- Speciogynine and the Lab-Testing Conversation
- Misconceptions About Speciogynine
- How Researchers Are Studying Speciogynine in 2026
- Frequently Asked Questions
- Final Thoughts
TL;DR
- Speciogynine is a minor kratom alkaloid found in mitragyna speciosa leaves. Every kratom strain you've taken contains it in trace amounts, even when the label only lists mitragynine.
- It belongs to the same indole-alkaloid family as mitragynine, paynantheine, and speciociliatine, but at a meaningfully lower concentration than the family's headline molecule.
- Research on speciogynine's standalone effects is sparse compared to mitragynine. What exists points to weak opioid receptor activity plus some serotonergic affinity, mostly in animal and tissue models.
- A metabolite called speciogynine pseudoindoxyl has shown stronger receptor activity in early lab work. There are no human trials yet, only structure-activity studies.
- Most vendors only publish mitragynine percentage. Speciogynine numbers come from third-party COAs, peer-reviewed product audits, and academic phytochemistry work.
- Strain and vein color shift the alkaloid ratio, but postharvest handling shifts it more than people realize. Withering and drying conditions can move speciogynine concentration by a third or more.
- Speciogynine isn't a "secret strong" alkaloid. People who report unique effects from a strain are reading the combined alkaloid profile, not speciogynine alone.
- If alkaloid transparency matters to you, ask your vendor for a full panel COA, not just a mitragynine percentage. The full panel is the only honest read.
What Speciogynine Actually Is
Speciogynine is a naturally occurring monoterpenoid indole alkaloid found in mitragyna speciosa, the kratom tree native to Southeast Asia. Its molecular formula is C23H30N2O4, which puts it neatly inside the broader kratom chemical structure family. It was characterized alongside mitragynine in early phytochemistry surveys of Thai and Malay kratom leaves in the 1960s, and it's been quietly showing up in alkaloid panels ever since.
Quick chemistry note for the curious reader: an alkaloid is a nitrogen-containing plant molecule with pharmacological activity, which is a fancy way of saying "the part of the plant that does something to your receptors." Speciogynine sits inside the indole-alkaloid family, with mitragynine, paynantheine, and speciociliatine as its closest relatives. They share a core structure and differ in stereochemistry. Stereochemistry sounds esoteric, but it matters: small differences in molecular shape change how a molecule fits into receptor pockets, and that changes what the molecule does once it gets there.
How does speciogynine differ from mitragynine in one sentence? It's a stereoisomer with weaker mu opioid receptor affinity and stronger serotonergic activity. That's the short version. The long version is what the rest of this guide covers.
The numbers tell the size story bluntly. Across analyzed commercial kratom products, mitragynine is present at 0.7% to 38.7% by weight while speciogynine ranges from 0.1% to 5.3% (Frontiers in Pharmacology, 2021). In studies that isolate the diastereomers from raw leaf, the quantity of mitragynine isolated runs at least 20 times higher than that of speciogynine, paynantheine, or related compounds. So when researchers and lab analysts speak about speciogynine, they're speaking about a real alkaloid that's nonetheless a minority shareholder in the leaf.
A reference point worth bookmarking: in a 2019 ultra-performance liquid chromatography-tandem mass spectrometry quantification, ten key kratom alkaloids were measured simultaneously across leaf extracts and commercial products (Sharma et al., PubMed 30997725). It's the kind of paper a vendor's full-panel COA should be benchmarked against. If you've ever wondered what "rigorous alkaloid measurement" looks like in practice, that paper is the answer.
How speciogynine fits into the kratom alkaloid family
Mitragynine sits at the top of the family by mass, typically 60 to 70% of total alkaloid content depending on the leaf source. 7-hydroxymitragynine is the next-most-discussed alkaloid, present at low concentration in fresh leaf and somewhat higher in stored or oxidized leaf where mitragynine has had time to oxidize into its 7-OH form. After those two come the diastereomers: speciogynine, paynantheine, speciociliatine. They share mitragynine's core structure but differ in how the molecule is folded in three-dimensional space. That folding is everything in pharmacology. We point readers who want a deeper plant-side primer toward our Mitragyna Speciosa primer, which covers the source plant in more detail.
Speciogynine vs speciociliatine vs paynantheine
The three minor diastereomers are siblings, not strangers. They're stereoisomers of mitragynine that show up in research as having mild smooth-muscle and opioid-receptor activity in animal and tissue models. Paynantheine is the largest of the three by mass. Speciogynine and speciociliatine come in next. We won't claim ranked potency between the three because the human data isn't there. What we'll do is show the structure of the comparison in numbers. Reported speciociliatine effects in tissue studies look similar to speciogynine's, with mild mu opioid activity and modest smooth-muscle modulation.
| Alkaloid | Typical % of total alkaloid content | Receptor activity (preclinical) |
|---|---|---|
| Mitragynine | ~66% | Mu/delta opioid agonist; adrenergic α2 |
| Paynantheine | ~9% | Smooth-muscle relaxation; weak opioid |
| Speciogynine | ~7% | Weak mu opioid; serotonergic 5-HT1A / 5-HT2B activity |
| 7-Hydroxymitragynine | ~2% | Mu opioid agonist (potent) |
| Speciociliatine | ~1% | Weak mu opioid; mild smooth-muscle activity |
That table is what a kratom alkaloid panel actually measures. When a vendor tells you only the mitragynine percentage, you're seeing 66% of the picture. The other 34% is everything else, and "everything else" is where the strain-to-strain feel differences live.
What Researchers Know About Speciogynine's Effects
Honest summary first. Animal-model work has shown speciogynine binding at mu and delta opioid receptors with affinity weaker than mitragynine. Tissue studies have shown smooth-muscle relaxation in guinea pig ileum, a classic kratom pharmacology assay. One peer-reviewed lab paper has flagged speciogynine pseudoindoxyl, an oxidation metabolite, as having stronger receptor activity than the parent alkaloid. Human trials? None we can cite. Not one. We say that out loud because we'd rather you know the gap than guess at it.
The numbers are what makes the picture clear. In binding studies at the human mu opioid receptor, speciogynine sat at a Ki of 728 nM, meaningfully weaker than mitragynine (Ki 233 nM) and far weaker than 7-hydroxymitragynine (Ki 47 nM) (Frontiers in Pharmacology, 2022). Lower Ki means stronger binding, so a Ki of 728 nM tells you speciogynine isn't doing much heavy lifting at mu. What it's doing instead, interestingly, is hitting serotonergic targets. Speciogynine has shown affinity at 5-HT1A and 5-HT2B receptors that mitragynine itself doesn't show, which is one of the reasons researchers are still interested in it.
| Alkaloid | Ki at human mu opioid receptor (nM) | Functional activity |
|---|---|---|
| 7-Hydroxymitragynine | 47 | Mu agonist |
| Mitragynine | 233 | Partial mu agonist; biased signaling |
| Speciogynine | 728 | Weak mu activity; serotonergic 5-HT1A/5-HT2B affinity |
| Paynantheine | similar weak range | Smooth-muscle activity |
Worth knowing.
What "speciogynine effects" probably feels like (and why we're hedging)
Honest answer: nobody knows for sure, because nobody has ever been dosed with isolated speciogynine. Speciogynine never appears alone in kratom leaf. What people describe when they say a kratom strain feels "different" is the combined alkaloid profile, not a single minor compound.
Community discussions on kratom forums sometimes attribute strain-specific feelings ("more body relaxation," "less head buzz") to higher speciogynine ratios. We treat that as anecdote, not evidence, and we'd encourage anyone reading those threads to do the same. The 2022 Frontiers review cited above explicitly cautions against pinning subjective effects to single minor alkaloids until human dose-response work is published. That caution applies just as hard in 2026 as it did when the review went to press.
Speciogynine pseudoindoxyl, briefly
Pseudoindoxyl is a fancy word for an oxidation product. Speciogynine pseudoindoxyl forms when the alkaloid oxidizes during storage or processing, similar to how 7-hydroxymitragynine forms from mitragynine. Lab data so far suggests stronger receptor affinity than the parent alkaloid, but the keyword there is "lab data." No clinical trials. No measured presence in commercial kratom products outside research labs.
The 2016 Váradi et al. paper in the Journal of Medicinal Chemistry showed that mitragynine and corynantheidine pseudoindoxyl analogs acted as mu agonists with delta antagonism that didn't recruit β-arrestin-2, a signaling pattern of interest for analgesia with reduced side-effect risk (PMC5344672). The authors went on to extend the structure-activity work to speciogynine and paynantheine templates, a research thread still active in 2025 and 2026. Useful for the reader to know the term exists when reading alkaloid forums. Not actionable today.
Where Speciogynine Sits in Real Kratom Products
Now we move from chemistry to commerce. Vendors test for mitragynine percentage almost universally. Almost nobody publishes a full alkaloid panel that includes speciogynine. The reasons are practical: LC-MS instrument time costs money, regulatory expectations are still in flux, and marketing departments have decided that "X% mitragynine" is the easy buy signal that consumers respond to.
A careful buyer can still get speciogynine numbers. There are three reliable routes. First, third-party COA programs that publish full panels. Second, GMP-certified vendors who partner with accredited labs and post complete results. Third, peer-reviewed papers that have tested specific commercial products and published their findings. The numbers below come from the second and third routes blended together, and they're what a serious COA looks like.
| Alkaloid | Typical range (% w/w in product) |
|---|---|
| Mitragynine | 0.7 – 38.7% |
| 7-Hydroxymitragynine | 0.01 – 1.5% |
| Speciogynine | 0.1 – 5.3% |
| Paynantheine | 0.3 – 12.8% |
| Speciociliatine | 0.4 – 12.3% |
Two reads of that table. First, speciogynine concentration overlaps with paynantheine and speciociliatine in product samples, which is the messy reality of plant chemistry. Second, the absolute percentages aren't what to focus on. What matters is whether the panel exists at all. A vendor who publishes the full ranges has nothing to hide. A vendor who publishes only mitragynine has everything still to disclose. We've covered the safety side of that disclosure question in our Kratom Side Effects guide.
How strain and vein color shift speciogynine concentration
Soil, tree maturity, harvest timing, and vein color all change the leaf's alkaloid ratio. Red-vein leaves often test slightly higher in non-mitragynine alkaloids, including speciogynine. Green and white veins tend to show different ratios. White veins, in particular, often run higher in mitragynine percentage but lower in the diastereomer fraction. We avoid claiming a strain is "the speciogynine strain" because nobody markets it that way and the chemistry doesn't support such tidy labeling.
Postharvest handling shifts the ratio more than people realize. A 2025 Frontiers in Plant Science study found that a 12-hour withering period followed by drying below 40°C enhanced speciogynine and paynantheine in one Hawaii cultivar by 37 to 48% and 35 to 67%, respectively (PMC12516786, 2025). Translation: how a farmer dries a leaf can move the speciogynine concentration by a third or more. Vein color matters less than the cultivation paper trail.
Speciogynine and the Lab-Testing Conversation
If full alkaloid transparency matters to you as a buyer, this section is the practical one. The COA (Certificate of Analysis) is the document a vendor publishes alongside each product batch, and a serious COA tells you everything that matters about that batch in one page.
Here's what a complete COA shows:
- Total alkaloid content (% w/w of dried leaf)
- Mitragynine percentage
- 7-Hydroxymitragynine percentage
- Speciogynine percentage
- Speciociliatine percentage
- Paynantheine percentage
- Heavy metal panel (lead, arsenic, cadmium, mercury)
- Microbial panel (total aerobic count, yeast, mold)
- Pathogen testing (salmonella, E. coli)
- Method and instrument (LC-MS or UPLC-MS preferred over HPLC alone)
- Lab name plus ISO 17025 accreditation status
- Test date and product lot number
If items 4 through 6 aren't on the COA, you're seeing a partial panel. That doesn't necessarily mean the product is bad. It means the alkaloid profile beyond mitragynine is undisclosed, and you're trusting the vendor to be careful about something they aren't reporting. Your call whether that trust is earned.
What a "complete COA" should show
The checklist above is descriptive, not promotional. It's what a serious lab partner would deliver and what a serious vendor would post. If you find yourself asking a vendor for that and getting hedged answers, that's a useful signal. Here's a short template you can copy into a customer-service email or chat:
- "Do you publish a full alkaloid panel, including speciogynine, speciociliatine, and paynantheine, for every batch?"
- "What instrument is used for the alkaloid panel: HPLC, LC-MS, or UPLC-MS?"
- "Is the lab ISO 17025 accredited?"
- "Can you share the COA before purchase, or only after?"
- "What's the lot number on the product I'd be buying, and does it match a posted COA?"
Five questions. They take five minutes for a serious vendor to answer in an email. They take much longer (or never) for a less serious one.
Misconceptions About Speciogynine
Three myths come up enough on kratom forums to be worth correcting in print.
The first myth: speciogynine is the "secret strong" alkaloid that explains why some kratom strains feel more potent than others. Reality: speciogynine sits at a Ki of 728 nM at the mu opioid receptor and at a few percent of total alkaloid content by mass. Whatever's making a strain feel "potent" to a particular reader, it isn't speciogynine doing the heavy lifting on its own.
The second myth: speciogynine is what makes red-vein kratom different. Reality: red-vein leaves do tend to test slightly higher in non-mitragynine alkaloids, but the full ratio is what differs across vein colors, and postharvest handling shifts the ratio more than the vein color does. Pinning red-vein character on speciogynine alone is bad chemistry and worse marketing.
The third myth: more speciogynine means more potency. Reality: there's no clinical data that supports a dose-response curve for speciogynine in humans. Anyone selling you a product on the strength of its speciogynine percentage is selling you a story that the science can't back up yet.
Worth flagging because the same logic that fuels concentrated 7-OH marketing right now would fuel "high-speciogynine" marketing tomorrow if anyone tried. In July 2025 the FDA formally recommended that the DEA place 7-hydroxymitragynine on Schedule I of the Controlled Substances Act, focused on highly concentrated 7-OH products rather than whole-leaf kratom (FDA News and Events: FDA and Kratom). The misconception that "minor alkaloids equal stronger product" is the same logic that fueled concentrated 7-OH marketing. We'd rather not see it repeated with speciogynine. Our 7-OH Is Not Kratom guide covers the regulatory side of that story in depth.
How Researchers Are Studying Speciogynine in 2026
Four research threads are active right now, and they're worth knowing about even if none of them produces actionable consumer guidance this year.
The first thread is receptor binding mapping. Researchers continue to characterize how speciogynine and its diastereomers fit into the human opioid receptor system. A 2026 study in Frontiers in Pharmacology, "Multifaceted modulation of human opioid receptors by kratom alkaloids" (Frontiers in Pharmacology, 2026), is the most current published work mapping how the full kratom alkaloid panel, speciogynine included, modulates the human opioid receptor system. It's also the kind of paper that gradually closes the gap between "preclinical hunch" and "clinically meaningful."
The second thread is pseudoindoxyl pharmacology. Speciogynine pseudoindoxyl, paynantheine pseudoindoxyl, and their hydroxylated variants continue to be synthesized and tested in receptor assays. The structure-activity work from the Váradi group is the original spine of that thread, and several groups have built on it.
The third thread is cytochrome P450 metabolism. How fast speciogynine breaks down in human liver enzymes, and which enzymes do the breaking, matters for drug-drug interaction risk. Most of that work is still in vitro.
The fourth thread is analytical methods development. Better, cheaper, faster ways to quantify the full alkaloid panel in plant tissue and finished products. The 2019 UPLC-MS quantification paper opened that door, and the 2025 Frontiers postharvest paper kept walking through it.
We aren't predicting outcomes. We're describing the work being done. Most of what we know about speciogynine is preclinical, and that's worth saying out loud once more before we close.
Why this matters for the average kratom buyer
Practical takeaway. If speciogynine ends up confirmed as more bioactive through its pseudoindoxyl metabolite, regulatory and labeling expectations could shift over the next few years. Vendors who already publish full panels will be ahead of that curve. Vendors who publish only mitragynine will have catch-up to do.
For now, the buyer's lesson is short. Mitragynine percentage alone doesn't capture a kratom product's pharmacology. If you want to know what's actually in your kratom, look at vendors who publish complete alkaloid panels including speciogynine, speciociliatine, paynantheine, and 7-hydroxymitragynine. The full panel is the read.
Frequently Asked Questions
Is speciogynine the same as mitragynine?
No. Speciogynine and mitragynine are stereoisomers, which means they share the same molecular formula but differ in three-dimensional shape. That shape difference matters for receptor binding. Speciogynine has weaker mu opioid receptor affinity and stronger serotonergic activity than mitragynine.
What does speciogynine do?
Preclinical research shows speciogynine binds weakly to mu opioid receptors and shows affinity at 5-HT1A and 5-HT2B serotonin receptors. There are no human trials of speciogynine in isolation, so any subjective-effect claim is anecdotal. Speciogynine never appears alone in kratom; it's always part of the combined alkaloid profile.
Is speciogynine an opioid?
It's a weak mu opioid receptor binder in lab assays, with a Ki of 728 nM compared to mitragynine's 233 nM and 7-hydroxymitragynine's 47 nM. So technically speciogynine has opioid receptor activity, but it's much weaker than the alkaloids that drive most of kratom's pharmacology.
Which kratom strains have the most speciogynine?
There's no strain marketed as "high-speciogynine" because vendors typically don't publish per-alkaloid breakdowns. Red-vein leaves often test slightly higher in non-mitragynine alkaloids, and postharvest handling (especially withering and drying conditions) shifts speciogynine concentration more than vein color does. The honest answer is: ask for a full COA on a specific batch.
Can speciogynine be measured in lab testing?
Yes. UPLC-MS and LC-MS instruments routinely quantify speciogynine alongside mitragynine, 7-hydroxymitragynine, paynantheine, and speciociliatine. The 2019 Sharma et al. paper standardized the method for ten key kratom alkaloids. The barrier isn't analytical capability; it's that vendors usually don't publish the full panel.
What is speciogynine pseudoindoxyl?
It's an oxidation metabolite of speciogynine, formed when the alkaloid oxidizes during storage or processing. Lab work suggests it has stronger receptor affinity than the parent alkaloid, similar to how 7-hydroxymitragynine relates to mitragynine. There's no clinical data and no measured presence in commercial kratom products outside research labs.
Is speciogynine safe?
Speciogynine has been in every kratom leaf people have consumed for centuries, so any safety profile of kratom as a whole includes whatever speciogynine contributes. There's no evidence of unique speciogynine-specific risk in the published literature. There's also no evidence of unique speciogynine-specific benefit. Treat it the way you'd treat any minor alkaloid: as part of the full panel that determines a product's overall pharmacology.
Final Thoughts
Speciogynine is real. It's in every kratom leaf. The human evidence is sparse, the preclinical evidence is consistent, and there's no proven standalone effect to chase. The honest summary fits in three lines, and we've now spent a few thousand words backing each line up with sources.
The pain point we're sitting next to is the bigger one for any kratom buyer in 2026: labels rarely tell you what's actually in your product. Mitragynine percentage isn't enough to know what your kratom is doing. The full alkaloid panel is.
GRH Kratom publishes full lab panels for every batch, including speciogynine, speciociliatine, paynantheine, and 7-hydroxymitragynine alongside mitragynine. If you want to see what alkaloid transparency actually looks like in practice, the COAs are linked from every product page at grhkratom.com. Read one before you buy your next batch from any vendor, ours or someone else's. The full panel is the read.
